GET DAILY SIGNALSNational Vision Holdings (EYE): Analyst Consensus Points to +55% Upside to $28 Target
Key Takeaways
- The central price target of $28 is the arithmetic mean of 10 verified analyst price targets, calculated from individual targets ranging from $20 to $35 and rounded from roughly $27.60.
- At a recent price near $18, reaching $28 would require an upside of about 55%, a very large move by any standard.
- Analyst views are unusually wide: cautious holds sit as low as $20–$21, while bullish firms such as Citi and UBS carry targets of $35 and $34, respectively.
- The strongest supporting factors are accelerating margin expansion, high-single-digit growth in managed care customers, and a pull-forward of new store openings to 50–55 in 2027.
- The biggest risks are a persistent decline in customer traffic, a second consecutive cut to full-year guidance, and a weaker, price-sensitive consumer.
- For more context on this ticker, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
- To see how AI-driven signals are tracking this and other names, explore Trending AI Robots.
Analyst Price Targets and Consensus View
National Vision Holdings, Inc. (NASDAQ: EYE) operates America’s Best Contacts & Eyeglasses, Eyeglass World, Vista Optical, and DiscountContacts.com. The latest analyst targets include UBS at $34, Citi at $35, Morgan Stanley at $21, Bank of America at $30, Barclays at $27, Roth MKM at $27, Wells Fargo at $20, Jefferies at $31, Guggenheim at $27, and Goldman Sachs at $24. The average of these ten figures comes to roughly $27.60, which rounds to a central target of $28, with a low of $20 and a high of $35.
The range highlights clear differences in outlook. Firms such as Morgan Stanley and Wells Fargo, both with Hold or Equal-Weight ratings, focus on soft traffic and pressure on self-pay customers. More bullish voices at Citi and UBS emphasize margin gains, a better customer mix, and steady ticket growth. Several targets have been lowered during 2026 as traffic slowed, yet the overall rating stays at Buy because of confidence in the company’s ability to improve profitability even without strong unit growth. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Shares traded near $18 following third-quarter 2026 results, within a 52-week range of about $14.75 to $30.02. Reaching the $28 target from recent levels would mean an advance of roughly 55%, a sizable move that would place the stock near the upper end of its recent trading range.
The route to that level appears tied more to profitability than to traffic recovery. In Q3 2026, adjusted EPS more than doubled year over year to $0.30, beating consensus, while adjusted operating margin rose 320 basis points to 7.3%. Revenue increased 4.8% to $510.5 million but fell short of estimates, and the company reduced its full-year adjusted comparable-store-sales growth outlook to 2%–3%. From what I see, sustained margin improvement will be essential to offset ongoing weakness in store visits.
What Could Support a Move Toward the Target
- Margin and EPS momentum: adjusted operating income nearly doubled, supported by ticket growth of almost 9% driven by product mix rather than price increases.
- Managed care growth: this higher-value group is expanding in the high single digits with positive traffic trends, lifting overall economics per transaction.
- Accelerated expansion: management advanced store openings to approximately 50–55 in 2027, moving the timeline forward by a year.
- Category innovation: a Meta co-marketing partnership for smart eyewear and a new $195 designer complete-pair offering expand the product range.
- Capital returns: a newly authorized $100 million share repurchase program reflects management’s view on current valuation.
What Could Prevent the Target From Being Reached
- Shrinking traffic: traffic declined 5.6% in Q3, a steeper drop than earlier quarters and concentrated among lower-value self-pay customers.
- Guidance cuts: full-year revenue and adjusted-EPS forecasts were trimmed for the second consecutive quarter, pointing to a near-breakeven fourth quarter.
- Consumer softness: longer purchase cycles and broader pressure on cash-pay shoppers could continue into 2027.
- Competition: online and vertically integrated eyewear providers continue to take share from traditional stores.
- Valuation: a trailing P/E above 30 leaves limited room for any execution shortfalls.
Technical Levels and Market Structure
The 52-week range of roughly $14.75 to $30.02 sets the context. The $30 area, close to the prior peak, sits just above the $28 target and could serve as resistance on any rally. Support has held in the mid-to-high teens, with the $14.75 low acting as a longer-term floor. A sustained move toward the target would likely first require reclaiming the low-to-mid $20s, the zone where the stock has spent much of the past year.
Time Horizon and What Investors Should Monitor
Analyst targets typically cover a 12-month horizon, though assumptions about store growth, margins, and valuation multiples differ across firms. Items worth watching include quarterly traffic and ticket trends, whether the accelerated 2027 store openings remain on track, progress with the Meta partnership and new segmentation efforts, and any further adjustments to full-year guidance. Broader consumer spending data and sector commentary on discretionary retail will also matter for the self-pay customer segment.
Final Assessment
The $28 central target, derived from the analyst targets reviewed above the current price near $18, implies a gain of roughly 55%. Support comes from tangible improvements such as stronger EPS, expanding margins, managed care momentum, and faster store growth. The challenges remain equally clear: declining traffic, repeated guidance reductions, and a cautious consumer environment. With targets spread from $20 to $35, the Street remains divided on whether the profitability story can overcome demand weakness. The target becomes realistic only if margin discipline continues to turn fewer visits into higher earnings, something I’m watching closely in the quarters ahead.
Using AI Daily Buy/Sell Signals in My Research
I regularly turn to Tickeron’s AI Daily Buy/Sell Signals to monitor how market conditions and technical factors are shifting for names like EYE. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals that help complement fundamental work and highlight potential changes in trend more quickly than manual review alone.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
EYE in upward trend: price rose above 50-day moving average on November 04, 2026
EYE moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend. In 40 of 43 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on EYE as a result. In 63 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for EYE just turned positive on November 04, 2026. Looking at past instances where EYE's MACD turned positive, the stock continued to rise in 35 of 45 cases over the following month. The odds of a continued upward trend are 78%.
The 10-day moving average for EYE crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 84%.
Following a +6.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where EYE advanced for three days, in 204 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
EYE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 162 of 263 cases where EYE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Bearish Trend Analysis
The 10-day RSI Indicator for EYE moved out of overbought territory on October 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 25 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EYE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. EYE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.578) is normal, around the industry mean (2.289). P/E Ratio (28.413) is within average values for comparable stocks, (17.578). EYE's Projected Growth (PEG Ratio) (0.050) is slightly lower than the industry average of (1.159). Dividend Yield (0.000) settles around the average of (0.102) among similar stocks. P/S Ratio (0.657) is also within normal values, averaging (1.057).
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EYE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an operator of retail locations offering eye exams, eyeglasses and contact lenses
Industry SpecialtyStores
Advertisement